Ecnoglutide Dosage, half-life & reference guide

Also known as XW003 · XW004 · VRB-101 · Ecno

Reviewed 6 studiesEvidence: EstablishedPublished by PepVault

A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.

Studied range
0.6–2.4 mgstarting dose 0.3 mg
How often
Weekly
Half-life
~5.5 days
Evidence
●●● Established
Route
SubQ injection

Studied in research — not a recommendation.

Ecnoglutide dose guide

How it works.

Once-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials.

Commonly reported: Appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.

Half-life & active level

The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).

Here's how a typical Ecnoglutide schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Ecnoglutide works.

A body with Appetite & metabolism lit
  • Appetite & metabolism

    In people. A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Days–2 weeks
Peak effect
48 weeks (phase 3, no plateau)
Duration
Ongoing
  1. Day 1–28 · 0.3 mgRCT

    A low first month

    You're on 0.3 mg, the first step in ecnoglutide's diabetes trials. Commonly reported: appetite dropping within days. In those trials, GI side effects came mainly while the dose was stepping up and faded after.

    The science

    Phase 3 vs placebo in type 2 diabetes (Zhu 2026, Nat Commun; NCT05680155): "a slow dose-escalation regimen, starting at 0.3 mg ... with fixed double-dose increments every 4 weeks"; GI adverse events "mainly occurred in the dose escalation period and diminished over time".

    Sources
    • Zhu et al. (2026)

    Updated Nov 2026

  2. Day 29–56 · 0.6 mgRCT

    Doubling to 0.6 mg

    You're at 0.6 mg, the second step, and one of the maintenance doses tested in type 2 diabetes. Commonly reported: a few queasy days after the step, then steadier appetite.

    The science

    In the type 2 diabetes trial, the 0.6 mg maintenance dose was reached at week 4 and 1.2 mg at week 8 (Zhu 2026). Pulse rose slightly on ecnoglutide, consistent with the GLP-1 class, and no severe hypoglycaemia was reported.

    Sources
    • Zhu et al. (2026)

    Updated Nov 2026

  3. Any dayRCT

    What Ecnoglutide is built on

    Phase 1 and 2 trials, a phase 3 obesity trial of 664 people, and two phase 3 diabetes trials, one against dulaglutide. China approved it in 2026. It is not FDA-approved.

    The science

    Discovery: a GLP-1 analogue with Val8 and a lysine-30 fatty acid, cAMP-biased with less receptor internalisation (Guo 2023, Mol Metab). SLIMMER (Ji 2025; NCT05813795, sponsor Hangzhou Sciwind Biosciences). Type 2 diabetes: vs placebo (Zhu 2026, Nat Commun) and vs dulaglutide (He 2025, Lancet Diabetes Endocrinol). Approvals: China, January 2026 (type 2 diabetes) and March 2026 (weight management) (Shirley 2026, Drugs). Interaction studies: Chen 2026 (warfarin, metformin), Li 2026 (rosuvastatin, digoxin).

    Sources
    • Guo et al. (2023)
    • Ji et al. (SLIMMER) (2025)
    • Zhu et al. (2026)
    • He et al. (2025)
    • Shirley (2026)

    Updated Nov 2026

  4. With BPC-157Community

    Why people add BPC-157 to a GLP-1

    GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

    The science

    BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside ecnoglutide or any GLP-1 drug; the pairing comes from community reports.

    Sources
    • Sikiric et al. (2018)

    Updated Nov 2026

After week 8

  1. Day 57–336 · 1.2 mgRCT

    The lowest weight-loss dose

    You're at 1.2 mg, the lowest dose in the obesity trial. That group lost about 9% of body weight by week 40, and about three in four lost at least 5%.

    The science

    SLIMMER (Ji 2025, Lancet Diabetes Endocrinol; 664 adults without diabetes, 36 centres in China): 1.2 mg −9.1% at week 40 vs +0.1% on placebo (difference −9.2%); 77% reached ≥5% loss vs 16% (treatment-policy estimand).

    Sources
    • Ji et al. (SLIMMER) (2025)

    Updated Nov 2026

  2. Day 85–336 · 1.8 mgRCT

    The middle dose

    You're at 1.8 mg. In SLIMMER, that group lost about 11% by week 40, and 84% lost at least 5%.

    The science

    SLIMMER week 40: 1.8 mg −10.9% vs +0.1% on placebo (difference −11.1%); 84% reached ≥5% vs 16% (Ji 2025).

    Sources
    • Ji et al. (SLIMMER) (2025)

    Updated Nov 2026

  3. Day 85–336 · 2.4 mgRCT

    The top dose

    You're at 2.4 mg, the highest dose in the obesity trial. That group lost about 13% by week 40 and about 15% by week 48, and was still losing. About two in three lost at least 15%.

    The science

    SLIMMER: 2.4 mg −13.2% at week 40 vs +0.1% (difference −13.3%), 87% ≥5% (Ji 2025). At week 48 (treatment-policy): −15.4% (placebo-adjusted −15.1%), 92.8% ≥5%, 79.6% ≥10%, 63.5% ≥15%, no plateau; liver fat −53.1% at week 40 in those starting at 8% or more (Sciwind, Mar-6-2026).

    Sources
    • Ji et al. (SLIMMER) (2025)
    • Sciwind (approval release) (2026)

    Updated Nov 2026

  4. Day 337+Clinical

    A long-term medicine, not a course

    Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Ecnoglutide hasn't been tested in a stopping trial, so this is the pattern of the class. Continue, taper or stop is a call for you and your clinician.

    The science

    A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). A weight-maintenance trial of oral ecnoglutide (NCT07553299) was terminated early in 2026.

    Sources
    • West et al. (2026)

    Updated Nov 2026

Day 1 is the day you start it.

Phase 3 SLIMMER (Ji 2025, Lancet Diabetes Endocrinol), phase 3 in type 2 diabetes (Zhu 2026, Nat Commun; He 2025, Lancet Diabetes Endocrinol), approvals (Shirley 2026, Drugs), Sciwind release Mar-6-2026, interaction studies (Chen 2026; Li 2026). The Chinese label was not read.

Clinical trial data

Mixing and a typical run.

Example numbers

Reconstitution example

Reconstitute a 10 mg vial of Ecnoglutide with 2 mL of bacteriostatic water and a 0.3 mg dose is 6 units on a U-100 syringe, about 33 doses per vial.

Vial
10 mg
Water
2 mL
Amount
0.3 mg

Draw to6 units

0.3 mL insulin syringe · 30 units

Mix it in the Reconstitution LabOpen the calculator

Run notes

Cycle
Used continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once weekly SubQ, same day each week, in its trials. The diabetes trials started at 0.3 mg and doubled every 4 weeks (0.6 mg by week 4, 1.2 mg by week 8); the obesity trial used maintenance doses of 1.2, 1.8 and 2.4 mg. These are trial schedules; the Chinese label governs approved use there.
Route
SubQ injection
Stacks
BPC-157 (GI support)

Track it in the app

Safety.

Common side effects

  • Decreased appetite
  • Diarrhea
  • Nausea
  • Abdominal bloating
  • Weakness

Interactions

In interaction studies in healthy people, ecnoglutide did not change warfarin or metformin enough to need a dose change, and its effects on rosuvastatin and digoxin were studied too. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

Safety notes

In the 40-week SLIMMER phase 3 trial in China, side effects of any kind were reported by 93% on ecnoglutide and 84% on placebo, mostly mild-to-moderate GI events; ten people on ecnoglutide stopped because of side effects. In the diabetes trials, GI side effects came mainly in the step-up period and faded, there was no severe low blood sugar, and pulse rose slightly, as with other GLP-1 drugs; a rise in the lab value lipase was more common than on placebo (about 12% vs 3%), worth knowing if a blood test shows it. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

Mixing charts by vial size.

Questions people ask.

What is Ecnoglutide?

A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.

How is Ecnoglutide dosed in research?

The research range for Ecnoglutide is 0.6–2.4 mg, weekly, with a 0.3 mg starting dose. Studied in research — not a recommendation.

How long does Ecnoglutide last?

The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).

What do people report on Ecnoglutide?

Commonly reported on Ecnoglutide: appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.

Is Ecnoglutide safe?

The research basis for Ecnoglutide is established: clinical trials or FDA-approved use exists. Common side effects in the library: decreased appetite, diarrhea, nausea, abdominal bloating and weakness.

What does Ecnoglutide stack with?

Common stacks for Ecnoglutide: BPC-157 (GI support).

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Weekly

Half-life

~5.5 days

~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026)

Research basis

●●● Established

Clinical trials or FDA-approved use exists

PepVault for iPhone

Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library